New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced ...

ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

Enrollment completed across 18 clinical sites with 40+ investigators in the US, Canada, and New Zealand If the GPX ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...

Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241) who received care at the University of Chicago (UChicago) or the ...

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support ...